We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02424617
Recruitment Status : Completed
First Posted : April 23, 2015
Last Update Posted : August 18, 2022
Information provided by (Responsible Party):
BerGenBio ASA

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 25, 2021
Actual Study Completion Date : August 25, 2021
Certification/Extension First Submitted : August 16, 2022